Bitso, the largest Argentine cryptocurrency platform in Latin America by volume, has reached a market valuation of 2,200 million dollars, becoming the first Latin American cryptocurrency firm to achieve the status of “unicorn” by exceeding 1,000 million dollars of capitalization.

The company’s new valuation follows a $ 250 million ‘Series C‘ funding round led by Tiger Global and Coatue.

For his part, Coatue’s general partner, Michael Gilroy, highlighted that Bitso “is the first platform with scalable compliance systems that allows consumers throughout Latin America to access the crypto economy.”

“We believe that access to this financial product has the potential to change the rules of the game in Latin America and we look forward to supporting the Bitso team in its mission to expand access to cryptocurrencies for everyone”, Gilroy said.

Bitso CEO, Daniel Vogel, highlighted the growth of the cryptocurrency ecosystem this year. “Bitso took six years to get its first million clients. Today, less than ten months later, we have surpassed 2 million users.”

Currently, the firm has a presence in Argentina, Mexico and Brazil, where it launched its operation last week. “This round will be used to expand our capabilities, our product offering and to continue to make cryptocurrencies useful throughout Latin America”, Vogel added.

K. Tovar

Source: dpa

La entrada Bitso crypto exchange reaches the “Unicorn” status apareció primero en Bitfinance.

The price of the shares of the pharmaceutical company Johnson & Johnson registered a fall of 2 % in the New York Stock Exchange after the regulators of the United States recommended to suspend the use of its vaccine against Covid-19.

Specifically, the laboratory’s titles stood at $ 156.86 at the opening, compared to the 161.64 registered at the end of Monday (-2.95 %).

After that initial decline, the price has softened its fall, but has remained close to a 2 % drop until the mid-session.

The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) recommended this week to suspend the administration of the vaccine Janssen, from Johnson & Johnson, after having detected six possible cases of thrombi in patients inoculated with the vaccine.

The number detected, and whose cause is not yet certain, is enormously low compared to the 6.8 million injections of the vaccine that have been administered in the United States.

Following that suspension recommendation, Janssen decided to delay the launch of its Covid-19 vaccine in Europe.

K. Tovar

Source: dpa

La entrada Johnson & Johnson’s stock market value falls apareció primero en Bitfinance.